An Open-label, Pilot Pharmacokinetic Study to Determine the Bioavailability, Safety, and Tolerability of a Single Dose of Oradoxel in Metastatic Prostate Cancer Patients Treated With Intravenous Docetaxel
Latest Information Update: 30 Nov 2021
At a glance
- Drugs Docetaxel (Primary) ; HM 30181A (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Athenex
- 29 Nov 2021 Status changed from recruiting to completed.
- 04 Jun 2021 According to an Athenex media release, data from the study were presented at American Society of Clinical Oncology (ASCO) 2021.
- 04 Jun 2021 Results published in an Athenex Media Release.